1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Salix Pharmaceuticals, Ltd. - Strategy and SWOT Report

Salix Pharmaceuticals, Ltd. - Strategy and SWOT Report

  • February 2016
  • -
  • MarketLine
  • -
  • 25 pages

Introduction

Salix Pharmaceuticals, Ltd. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Salix Pharmaceuticals, Ltd. required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Salix Pharmaceuticals, Ltd. in the form of a SWOT analysis

- An in-depth view of the business model of Salix Pharmaceuticals, Ltd. including a breakdown and examination of key business segments

- Intelligence on Salix Pharmaceuticals, Ltd.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Salix Pharmaceuticals, Ltd., such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Salix Pharmaceuticals (Salix or 'the company') is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of prescription pharmaceutical products for the treatment of gastrointestinal diseases. The company's marketed drugs include Xifaxan, Osmoprep and Metozolv ODT. Salix primarily operates in the US, where it is headquartered in Raleigh, North Carolina. It employed about 1,000 people as of December 31, 2014. The company recorded revenues of $1,133.5 million during the financial year ended December 2014 (FY2014), an increase of 24% over FY2013. The operating loss of the company was $490.1 million in FY2014, as compared to an operating profit of $252.3 million in FY2013. The net loss of the company was $414.9 million in FY2014, as compared to a net profit of $130.8 million in FY2013.

Reasons to Purchase:

- Gain understanding of Salix Pharmaceuticals, Ltd. and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess Salix Pharmaceuticals, Ltd. as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on Salix Pharmaceuticals, Ltd.’s business structure, strategy and prospects

Table Of Contents

Salix Pharmaceuticals, Ltd. - Strategy and SWOT Report
Company Overview
Business Description
History
Key Employees and Biographies
Company View
Locations and Subsidiaries
SWOT Analysis
Revenue Analysis
Key Competitors
Major Products and Services

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.